الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 101 |  |  |
| | | from | 101 | | |
Abstract
Breast cancer is the most frequently diagnosed cancer globally and is the leading cause of cancer-related death in women. The American Cancer Society estimates that 249,260 Americans will be diagnosed with invasive breast cancer and 40,890 will die of the disease in the United States in 2016.
To review the demographic data and Clinico-pathological features of breast cancer patients with liver metastasis presented to Clinical Oncology and Nuclear Medicine Department, Alexandria Main University Hospitals from January 2006 to December 2015. To review all the treatment lines received by these patients. To assess the treatment results of different therapeutic strategies delivered to these patients (response rate, relapse free survival, OS and treatment side effects). To develop an electronic data sheet for these patients as a part of computerized system for future data entry.
Files of metastatic breast cancer patients with liver deposits presented to ACOD where investigated, keeping patients’ confidentiality, with a total of 124 patients along the 10 years of our study. Demographic data and pathological data were recorded. In addition, treatment details and survival outcomes for all cases were recorded.
Metastatic breast cancer was found to be close in both age groups; below and above 50 years with percentage 50.8% and 49.2% respectively.
In our study there is a higher percentage of cases with left side breast cancer which presented 59.7% of cases, Right side 38.7% and bilateral Breast Cancer 1.6%.
Pathologically, IDC represents % and ILC %. Hormonal profile including ER, PR and Her2 were investigated. In our study 51.6% of the patients were positive for ER receptor and 56% for PR receptor. Concerning Her2 receptor status, 16.9% of MBC patients were proven to show HER2 overexpression.